Format

Send to

Choose Destination
See comment in PubMed Commons below
Mol Med Today. 1999 Aug;5(8):359-66.

Gene therapy for chronic myelogenous leukemia.

Author information

  • 1Division of Hematology, Oncology and Transplantation, Dept of Medicine and Cancer Center, University of Minnesota, Box 806 UMHC, 420 Delaware Street SE, Minneapolis, MN 55455, USA. verfa001@tc.umn.edu

Abstract

Chronic myelogenous leukemia (CML) is characterized by a balanced translocation that leads to the formation of the the BCR-ABL fusion gene. Although autografts can prolong the life of CML patients, patients relapse owing to malignant cells that persist in the graft and the host. This review discusses various experimental strategies that target the BCR-ABL gene or gene products that are downstream of it. Various strategies have been adopted to block BCR-ABL at the gene, mRNA and protein level. One promising strategy involves the cotransduction of a patient's hematopoietic stem cells (HSCs) with anti-BCR-ABL antisense sequences and a drug resistance gene. This might allow for the elimination of any residual disease in the graft or host by chemotherapy while rendering any drug-resistant, malignant CML HSCs functionally normal.

PMID:
10431169
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Support Center